Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.39 |
| ▸ | ABAT | P80404 | 1/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.36 |
| ▸ | TUBB | P07437 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619663 | 0.87 | CYP1A2 (0.41) | ALDH1A1KDM4ELMNATSHRSMN1; SMN2 | |
| SCHEMBL29957773 | 0.86 | ALDH1A1 (0.37) | ALDH1A1KDM4ELMNATSHRSMN1; SMN2 | |
| SCHEMBL2567300 | 0.86 | ALDH1A1 (0.37) | ALDH1A1KDM4ELMNATSHRSMN1; SMN2 | |
| SCHEMBL89165 | 0.82 | FDPS (0.38) | ALDH1A1KDM4ELMNATSHRSMN1; SMN2 | |
| SCHEMBL3698437 | 0.81 | LMNA (0.50) | ALDH1A1KDM4ELMNATSHRSMN1; SMN2 | |
| SCHEMBL6180772 | 0.81 | ALDH1A1 (0.45) | ALDH1A1KDM4ELMNASMN1; SMN2TDP1 | |
| SCHEMBL21034743 | 0.77 | EGFR (0.42) | ALDH1A1KDM4ESMN1; SMN2CYP2A6TDP1 | |
| SCHEMBL1573175 | 0.76 | LMNA (0.48) | ALDH1A1KDM4ELMNATSHRSMN1; SMN2 | |
| SCHEMBL23151972 | 0.76 | ALDH1A1 (0.39) | ALDH1A1KDM4ELMNATSHRSMN1; SMN2 | |
| SCHEMBL8137679 | 0.76 | ALDH1A1 (0.44) | ALDH1A1KDM4ELMNASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207430-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | DYNE THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20230226212-A1 | MUSCLE-TARGETING COMPLEXES AND USES THEREOF | DYNE THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| WO-2023112048-A1 | CRISPR-DCAS13 SYSTEM, COMPOSITION, AND METHOD TO INDUCE TRANSLATIONAL READTHROUGH ACROSS STOP CODONS | INDIAN INSTITUTE OF SCIENCE (IN) | 2023-06-22 | — | — | WO | disclosed |
| EP-4189401-A1 | MOLECULES TARGETING RIBOSOMAL PROTEIN RPL35/UL29 FOR USE IN THE TREATMENT OF DISEASES, IN PARTICULAR EPIDERMOLYSIS BULLOSA (EB) | KBHB Consult GmbH (AT) | 2023-06-07 | — | — | EP | disclosed |
| EP-4185329-A1 | MUSCLE-TARGETING COMPLEXES AND USES THEREOF | Dyne Therapeutics, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-4185330-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | Dyne Therapeutics, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-4087876-A1 | MUSCLE-TARGETING COMPLEXES AND USES THEREOF | Dyne Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022173818-A1 | USE OF BILIVERDIN REDUCTASE B INHIBITORS TO ALLOW MALARIA ERADICATION IN PATIENTS WITH G6PD DEFICIENCY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-08-18 | — | — | WO | disclosed |
| WO-2022023479-A1 | MOLECULES TARGETING RIBOSOMAL PROTEIN RPL35/UL29 FOR USE IN THE TREATMENT OF DISEASES, IN PARTICULAR EPIDERMOLYSIS BULLOSA (EB) | KBHB Consult GmbH (AT) | 2022-02-03 | — | — | WO | disclosed |
| US-20040220207-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-04 | — | — | US | disclosed |
| CN-1457339-A | Chemokine receptor binding heterocyclic compounds | ANORMED INC (CA) | 2003-11-19 | — | — | CN | disclosed |
| EP-1317445-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20030018046-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2003-01-23 | — | — | US | disclosed |
| WO-2002022600-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-03-21 | — | — | WO | disclosed |
| CN-1334798-A | Phenylglycine derivatives | HOFFMANN LA ROCHE (CH) | 2002-02-06 | — | — | CN | disclosed |
| US-6140353-A | USED AS MEDICAMENTS FOR THE TREATMENT AND/OR PREVENTION OF THROMBOSES, APOPLEXY, CARDIAC INFARCTION, INFLAMMATION AND ARTERIOSCLEROSIS OR AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2000-10-31 | — | — | US | disclosed |
| EP-0199324-B1 | NEW 2,5-DIARYL TETRYHYDROFURANS AND ANALOGS THEREOF AS PAF ANTAGONISTS | MERCK & CO. INC. (US) | 1991-10-02 | — | — | EP | disclosed |
| EP-0322033-A2 | New 2,5-diaryl tetrahydrofurans and analogs thereof as paf antagonists | MERCK & CO. INC. (US) | 1989-06-28 | — | — | EP | disclosed |
| EP-0199324-A2 | New 2,5-diaryl tetryhydrofurans and analogs thereof as paf antagonists | MERCK & CO. INC. (US) | 1986-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220207-A1 | Chemokine receptor binding heterocyclic compounds | CXCR3, ACKR3, CCR2 | ALDH1A1 1755/4885KDM4E 4709/4885LMNA 4836/4885 |
| US-20230226212-A1 | MUSCLE-TARGETING COMPLEXES AND USES THEREOF | MUSK, MYOF, MYLK2 | ALDH1A1 3861/4885KDM4E 3576/4885LMNA 505/4885 |
| US-20030018046-A1 | Chemokine receptor binding heterocyclic compounds | CXCR3, ACKR3, CCR2 | ALDH1A1 1755/4885KDM4E 4709/4885LMNA 4836/4885 |
| US-20240207430-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | UTRN, MUSK, MYOF | ALDH1A1 3903/4885KDM4E 2274/4885LMNA 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.